

# Matthias Werder Appointed CFO of BioVersys

Basel, Switzerland, November 05, 2018. 09:00 CET

## Matthias Werder Appointed CFO of BioVersys

BioVersys is strengthening its executive management team with the arrival of Matthias Werder as Chief Financial Officer as of November 1<sup>st</sup>, 2018. He will lead finance, human resources, legal and support the CEO in fundraising and corporate strategy.

With more than 20 years of international experience, he brings important hands-on fundraising, investment, CFO and COO experience. In healthcare, Matthias has provided transaction advice, executed major M&A transactions for private equity investors and supported fundraising activities for high growth, early stage companies, and audited well regarded stock quoted companies, the WHO and the Global Fund. Matthias is a Chartered Financial Analyst (CFA), Fellow Chartered Accountant and holds a master's in economics from the University of St. Gallen, Switzerland.

Matthias Werder, a Swiss national, brings extensive private equity experience and broad knowledge of the investor market. Matthias' prime mission will be to help BioVersys to further develop its investor base in a series B financing round.

Dr. Marc Gitzinger, CEO and co-founder of BioVersys: "We are delighted that Matthias has joined BioVersys during this important time in the company's development, as we move our candidate molecules through late stage preclinical development and prepare to initiate first Phase I clinical trials in the 2H 2019. Matthias brings significant experience as an already established CFO with transaction-based expertise in many sectors including healthcare, and a broad network that will help BioVersys to grow and further develop our corporate strategy".

Matthias comments: "I am excited to join BioVersys, an innovative, fast growing biotech company that is taking exciting steps towards soon being a clinical stage company with its own development projects in the area of high unmet medical need of antimicrobial resistance, where patients' lives continue to be at risk from a lack of innovative and effective treatment options."

Contact: Tina Moriconi, Assistant to CEO, Tel. +41 61 633 22 56; Mail: [info@bioversys.com](mailto:info@bioversys.com)

**BioVersys AG** is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced R&D programs are in preclinical development for nosocomial infections (hospital infections), and Tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2019 BioVersys plans to launch our first Phase I clinical trials and transition into a clinical stage company. BioVersys is located on the Technologiepark in the thriving biotech hub of Basel, please visit [www.bioversys.com](http://www.bioversys.com).